Merck's ($MRK) experimental cholesterol drug anacetrapib, part of a huge study that won't yield final data till 2017, is already an expensive, risky bet. But it may be even riskier than previously considered: A new study finds that the drug lingers in the bodies of patients long after they've stopped using it, sometimes even for years. Report